SARS-CoV-2 Mpro-IN-2 

SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent M^pro inhibitor (IC₅₀=0.40 μM) with good anti-SARS-CoV-2 activity (EC₅₀=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies^[1].

SARS-CoV-2 Mpro-IN-2 (0.01-100 μM; 4 h) shows low cytotoxicity in Vero E6 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SARS-CoV-2 Mpro-IN-2 (2 mg/kg; i.v.; single) exhibits clearance rate (CL), mean residence time (MRT), and half-life (t_1/2) are 3140 mL/h/kg, 0.40 h, and 0.36 h, respectively^[1].
SARS-CoV-2 Mpro-IN-2 (10 mg/kg; p.o.; single) is rapidly absorbed, with a time-to-maximum concentration (T_max) of 0.5 h, and shows a moderate pharmacokinetic profile including a favorable t_1/2 (1.73 h), a maximum concentration (C_max) 74.6 ng/mL, and an area under curve (AUC_0-t) of 235 ng h/mL^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

475.39

C₂₂H₂₀Cl₂N₄O₂S

2768834-39-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gao S, et al. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity. J Med Chem. 2022 Sep 15:acs.jmedchem.2c01146.  [Content Brief]